BioNTech (BNTX)
(Delayed Data from NSDQ)
$100.60 USD
+1.85 (1.87%)
Updated May 31, 2024 04:00 PM ET
After-Market: $100.51 -0.09 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
BioNTech SE Sponsored ADR [BNTX]
Reports for Purchase
Showing records 101 - 120 ( 154 total )
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
CHMP Recommends Booster Shots; Oncology Pipeline Updates; Reit Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Potential COMIRNATY FDA Approval for Children Expected in 4Q21; Reit Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
FDA Grants EUA to COMIRNATY Booster in Select Populations; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
COMIRNATY Full Approval; Booster Rollout Next Month; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
COVID-19 Booster Shots Approved; ACIP Meeting Takeaways; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
COMIRNATY Full FDA Approval and Booster Plan Near-Term; Raising PT to $330
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Cell Therapy Platform and Manufacturing Facility Acquisition; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
COMIRNATY Potential Full FDA Approval in January 2022; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
FDA Push Back on COVID-19 Boosters; Competitive Updates; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
ACIP Indicates Vaccine Benefit Trumps Myocarditis Risk; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Production Sites Approved; COVID-19 Vaccine Landscape Updates; Reit Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Vaccine Benefit Trumps Myocarditis Risk; ACIP Meeting June 18; Reit Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
1Q21 Financials; Reiterate Neutral; Instituting $194 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
Novel Coronavirus Variants Could Evade Vaccine Protection; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
BNT162b2 Lower Neutralizing Impact Against Novel Variant; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
New SARS-CoV-2 Strains Could Prove Good for Business; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: BioNTech SE Sponsored ADR
Industry: Medical - Biomedical and Genetics
BNT162b2 May Retain Effectiveness Against New Strains; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R